Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00444535 · ClinicalTrials.gov registry record · Phase 2
Lapatinib and Bevacizumab for Metastatic Breast Cancer
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT00444535 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 52 participants.
The verdict
NCT00444535, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
This study will examine the efficacy and safety of lapatinib and bevacizumab in patients with ErbB2-overexpressing breast cancer.
Interventions
- DRUG bevacizumab
- DRUG lapatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2007-02-27 |
| Est. Completion | 2020-06-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00444535
The ClinicalTrials.gov registry entry for NCT00444535 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which bevacizumab is the first listed.
NCT00444535 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00444535 about?
NCT00444535 is a clinical study titled "Lapatinib and Bevacizumab for Metastatic Breast Cancer". This study will examine the efficacy and safety of lapatinib and bevacizumab in patients with ErbB2-overexpressing breast cancer.
What is the current status of trial NCT00444535?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2007-02-27. Estimated completion is 2020-06-19.
What interventions are being tested in trial NCT00444535?
The interventions under investigation include: bevacizumab (DRUG), lapatinib (DRUG).
Who is sponsoring clinical trial NCT00444535?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.